Inventor · disambiguated record
Matthias Will
Also filed as: WILL MATTHIAS
1 granted patent·11 pending applications·2 citations·filing 2018–2022
20Inventor score
Top patents by PatentIndex Score
12 records- 0170US11168144B2Activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Nov 9, 2021·2 cites·39 claims
- 0255US2022387488A1Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignanciesCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 0355US2022378829A1Genetically engineered immune cells targeting cd70 for use in treating solid tumorsCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 0452US2019117789A1Activatable anti-cd166 antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 0552US2021100913A1Activatable anti-cd166 antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0648US2022387571A1Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70CRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 0748US2022162332A1Activatable anti-pdl1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0848US2023355761A1Cd70+ solid tumor therapy using genetically engineered t cells targeting cd70CRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 0948US2022387572A1Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70CRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 1046US2022023439A1Activatable anti-cd166 antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1136US2022306745A1Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancerCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1236US2022296692A1Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancerCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthias Will files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →